BRD4 and acute myeloid leukemia: However, regardless of the nature of the cooperative mutation, in vitro and in vivo analyses indicate that NPM1c AML is consistently susceptible to I-BET151 because the drug inhibits BRD4 rather than wild-type NPM1 (38).